Abstract

Since the survival rates of pediatric patients undergoing cancer treatment or hematopoietic stem cell transplantation (HSCT) have increased rapidly in recent decades, the late effects of treatment are now an important focus of patient care. Access to fertility preservation (FP) procedures as well as their financing differs considerably across Europe. However, some countries in Europe have recently changed the legal basis for financing FP procedures; therefore, the implementation of structures is mandatory to give patients access to FP. In this prospective cohort study, we characterized the process for establishing pediatric fertility counseling, including the development of an in-house standard procedure for recommendations regarding FP with potentially gonadotoxic treatment and valuating data from all FP counseling sessions. All data concerning patient characteristics (pubertal status, disease group) and recommendation of FP measures were prospectively collected and adoption of FP measures analyzed. Prior to the establishment of a structured process for FP in our pediatric oncology and stem cell transplantation center, there was no standardized FP counseling. We demonstrate that with the establishment of an inhouse standard procedure, it is possible to give consistent yet individualized FP counseling to approximately 90% of our patients facing gonadotoxic treatment, counseling over 200 patients between 2017 and 2019. This pilot study could potentially be adapted in other pediatric hematology, oncology, and stem cell transplantation centers to allow a more standardized handling of FP counseling for all patients facing gonadotoxic treatment.

Highlights

  • With the immense progress in therapeutic regimens in pediatric oncology, the survival rates have increased up to 80% [1]

  • We offered written material to further explore the topic

  • A total of 89.4% (N= 152) of the 170 oncological patients received fertility counseling within the first days of diagnosis, including detailed information regarding the gonadotoxicity of their treatment, and we offered fertility preservation (FP) procedures if indicated

Read more

Summary

Introduction

With the immense progress in therapeutic regimens in pediatric oncology, the survival rates have increased up to 80% [1]. Broader indications for various diseases in the malignant and especially the nonmalignant settings have led to an increasing number of patients treated worldwide [2] and to a better overall long-term outcome. The risk of infertility due to chemo- or radiotherapy depends on the underlying disease, age, sex, other comorbidities, and the choice and dosage of chemotherapeutics, as well as the determination of the radiation field [4, 5]. For patients undergoing HSCT, gonadotoxicity is mainly associated with alkylating agents (especially busulfan) and total body irradiation (12 Gy) and the overall risk of infertility after HSCT is 7080% [6]. Female patients who are exposed to gonadotoxic treatment experience subfertility with a diminished ovarian reserve at a younger age than the general female population [6]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call